You are here

  • Home
  • Archive
  • Volume 6, Issue 6
  • Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis

Article metrics

Article menu

Download PDFPDF

XML
Oncology
Research
Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis

 

Online download statistics by month:

Online download statistics by month: January 2018 to April 2024

AbstractFullPdf
Jan 2018676111
Feb 2018827219
Mar 2018858116
Apr 2018646225
May 201871688
Jun 2018615829
Jul 2018919115
Aug 2018807310
Sep 2018404016
Oct 2018444416
Nov 2018575714
Dec 201838387
Jan 2019292911
Feb 2019373516
Mar 2019473915
Apr 2019463910
May 2019423614
Jun 201938295
Jul 2019322711
Aug 201929258
Oct 2019323113
Nov 2019363412
Dec 201938388
Jan 202036359
Feb 2020464416
Mar 2020343114
May 2020423852
Jun 2020393733
Jul 2020222126
Aug 2020191919
Sep 2020423420
Oct 2020292917
Nov 2020423818
Dec 2020322920
Jan 2021272626
Feb 202117149
Mar 2021333024
Apr 2021242310
May 2021252511
Jun 202123246
Jul 2021884
Aug 2021222216
Sep 2021252514
Oct 2021282825
Nov 2021131319
Dec 2021575714
Jan 2022555313
Feb 2022373716
Mar 2022393317
Apr 2022383612
May 2022413318
Jun 2022262817
Jul 2022233017
Aug 2022233020
Sep 2022363233
Oct 202216167
Nov 2022212119
Dec 2022141612
Jan 202318177
Feb 202310106
Mar 2023192013
Apr 2023121212
May 2023131012
Jun 2023231915
Jul 2023333325
Aug 2023242116
Sep 202315166
Oct 202314116
Nov 2023565410
Dec 2023745520
Jan 2024293123
Feb 2024202310
Mar 2024312215
Apr 2024222216
Total265324981144